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Introduction: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) represents the most common hereditary form of cerebral small vessel disease characterized by early-onset
stroke and premature dementia. It is caused by mutations in the transmembrane receptor Notch3, which promote the
aggregation and accumulation of the Notch3 extracellular domain (Notch3-ECD) within blood vessel walls. This process
is believed to mediate the abnormal recruitment and dysregulation of additional factors including extracellular matrix
(ECM) proteins resulting in brain vessel dysfunction. Based on recent evidence indicating a role for the transforming
growth factor-β (TGF-β) pathway in sporadic and familial small vessel disease we studied fibronectin, fibrillin-1 and
latent TGF-β binding protein 1 (LTBP-1), three ECM constituents involved in the regulation of TGF-β bioavailability, in
post-mortem brain tissue from CADASIL patients and control subjects.
Results: Fibronectin and fibrillin-1 were found to be enriched in CADASIL vessels without co-localizing with Notch3-ECD
deposits, likely as a result of fibrotic processes secondary to aggregate formation. In contrast, LTBP-1 showed both an
accumulation and a striking co-localization with Notch3-ECD deposits suggesting specific recruitment into aggregates.
We also detected increased levels of the TGF-β prodomain (also known as latency-associated peptide, LAP) indicating
dysregulation of the TGF-β pathway in CADASIL development. In vitro analyses revealed a direct interaction between
LTBP-1 and Notch3-ECD and demonstrated a specific co-aggregation of LTBP-1 with mutant Notch3.
Conclusion: We propose LTBP-1 as a novel component of Notch3-ECD deposits and suggest its involvement in
pathological processes triggered by Notch3-ECD aggregation.
Keywords: Latent TGF-β binding protein 1 (LTBP-1), Small vessel disease, CADASIL, TGF-β signaling, Granular osmiophilic
material (GOM), Extracellular matrix (ECM)Introduction
Cerebral small vessel disease (SVD), a major cause of
stroke and vascular dementia, represents the most preva-
lent neurological disorder in aging societies and thus a
considerable health care problem [1,2]. Monogenic forms
of SVD such as cerebral autosomal dominant arterio-
pathy with subcortical infarcts and leukoencephalopathy
(CADASIL) are considered valuable model conditions
contributing to our understanding of SVD pathomechan-
isms [3,4]. CADASIL vessel pathology shows considerable* Correspondence: Christof.Haffner@med.uni-muenchen.de
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unless otherwise stated.overlap with sporadic SVD including progressive thicken-
ing of the tunica intima and tunica adventitia as well as
narrowing of the vascular lumen. These alterations are
likely a result of fibrotic events involving increased pro-
duction of extracellular matrix (ECM) proteins such as
collagens [5,6]. They are observed primarily in small pial
and penetrating arteries, arterioles and capillaries of the
brain resulting in reduced cerebral blood flow and white
matter damage [7,8].
The gene mutated in CADASIL, NOTCH3, encodes a
transmembrane receptor required for arterial differenti-
ation and maturation of vascular smooth muscle cells in
small arteries [9]. Pathogenic mutations predominantly
affect cysteine residues within individual epidermal
growth factor (EGF)-like repeats of the Notch3 extracellu-
lar domain (Notch3-ECD) [10,11] leading to Notch3-ECD. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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vessel walls [12]. Notch3-ECD aggregates coincide with
large electron-dense deposits known as granular osmio-
philic material (GOM), an invariant feature of CADASIL-
affected vessels [13-15]. The appearance of Notch3-ECD
aggregates prior to neurological symptoms in both pa-
tients [16,17] and mouse models [18-20] suggest that they
represent an early manifestation causative for disease
development.
The molecular mechanisms underlying Notch3-ECD
deposit formation and the pathological events leading to
vessel dysfunction are incompletely understood. A var-
iety of studies using cultured cells or mouse models
[19,21-23] have failed to detect alterations in signaling
capacity of CADASIL-mutant Notch3, although contra-
dictory results have been reported [24]. Moreover, re-
cently identified patients with hypomorphic NOTCH3
alleles do not show signs of CADASIL [25]. Thus, novel
pathogenic roles for mutant Notch3 rather than com-
promised Notch3 function have been proposed as the
primary determinant of the disease [9].
Using scanning for intensely fluorescent targets (SIFT),
a confocal technique developed for monitoring protein
multimerization in solution [26], we have recently reca-
pitulated the Notch3 aggregation process in vitro and
demonstrated its facilitation by CADASIL mutations
[27,28]. Moreover, we observed co-aggregation of the
matricellular protein thrombospondin-2 [28], a known
Notch3 interactor and regulator of ECM assembly [29],
providing experimental evidence for a pathological co-
aggregation mechanism. This is supported by recent re-
sults obtained from CADASIL brain material enriched
for Notch3-ECD deposits by sequential fractionation
[30]. Using a mass spectrometry detection approach, a
variety of proteins were found to co-fractionate with
Notch3-ECD and for two of them, TIMP-3 and vitronec-
tin, disease-related roles were proposed. Notch3-ECD
aggregation might thus represent the initiating event of
a continuative process involving the recruitment and se-
questration of proteins with important roles in normal
vessel function.
The dysregulation of the transforming growth factor-β
(TGF-β) signaling pathway, a key regulator of fibrotic
events in various organs including the vasculature [31],
has been suggested to contribute to SVD pathogenesis
[32]. Moreover, increased TGF-β activity has recently
been reported in cerebral autosomal recessive arteriopa-
thy with subcortical infarcts and leukoencephalopathy
(CARASIL), a recessively inherited SVD syndrome re-
lated to CADASIL [33,34]. A specific role of TGF-β in
CADASIL can be inferred from the fact that fibronectin,
fibrillin-1 and members of the latent TGF-β binding
protein (LTBP) family, important ECM components with
a role in TGF-β bioactivation [35], were among thefactors identified in the proteomic study on CADASIL
brains [30]. We now extend this finding using immunohis-
tological approaches on post-mortem brain material and re-
port a dramatic enrichment of fibronectin, fibrillin-1 and
LTBP-1 in CADASIL vessels. While fibronectin and fibrillin-
1 show an immunohistological staining pattern different
from Notch3-ECD suggesting accumulation due to fibrotic
events secondary to Notch3-ECD aggregation, a striking
co-localization with Notch3-ECD deposits was observed
for LTBP-1 indicating a role in Notch3-ECD-mediated
toxicity. This finding is further supported by analyses dem-
onstrating a direct interaction of LTBP-1 with Notch3-
ECD and a co-aggregation with mutant Notch3 in vitro.
Materials and methods
Brain samples and vessel isolation
Frozen brain samples of five genetically confirmed
CADASIL patients (CAD 1–5) and four age- and sex-
matched controls with no known cerebrovascular disor-
ders (Ctrl 1–4) as well as paraffin sections of cases 1–3
and controls 1–3, all from the frontal subcortex (see
Table 1), were provided by the Brain-Net Biobank (Ludwig-
Maximilians-University Munich) and the CADASIL brain
bank (INSERM, Paris) [30]. Their distribution and analysis
occurred according to the guidelines of the local ethical
committees. Due to limited amounts of obtained material,
microvessel isolation could only be performed from CAD
2–5 and Ctrl 1–4 samples. Following a modified version
of a previously described protocol [30], 100 mg brain tis-
sue were homogenized in 15 mL cold Minimum Essential
Medium (MEM) (Gibco, Life Technologies) in a glass tis-
sue grinder (Wheaton), homogenates adjusted to a final
concentration of 15% Ficoll and centrifuged at 6000 g and
4°C for 20 min. The pelleted vessels were resuspended in
phosphate-buffered saline (PBS)/1% BSA and transferred
onto a 40-μm nylon mesh (Corning Life Sciences). After
extensive washing with PBS, isolated vessels were col-
lected in a 50-mL tube and pelleted for 5 min at 3000 g.
The purity of the vessels was verified using a phase-
contrast microscope.
Immunohistological analysis
For immunofluorescence analysis of CAD 1–3 and Ctrl
1–3 samples, frozen 10-μm tissue sections were thawed
to room temperature and fixed for 15 min in 4% parafor-
maldehyde (PFA) (Morphisto), blocked with PBS/5%
donkey serum (Jackson ImmunoResearch) for 40 min
and probed with primary antibodies in PBS/1% donkey
serum overnight at 4°C. For detection, Alexa Flour 488-,
Cy3- or rhodamine-coupled secondary antibodies (Jackson
ImmunoResearch, 1:200) were applied for 1 h at room
temperature. After mounting in ProLong Gold antifade re-
agent (Life Technologies), slides were examined using an
inverse (Axiovert 200 M, Zeiss equipped with AxioCam
Table 1 Overview of autopsy cases
Description Sex Age NOTCH3 mutation Applications
CAD 1 M 64 R110C Histological stainings
CAD 2 F 66 D239_D253del Histological stainings, Western Blot
CAD 3 M 68 C144S Histological stainings, Western Blot
CAD 4 F 60 R153C Western Blot
CAD 5 F 70 C1261R Western Blot
Ctrl 1 M 61 - Histological stainings, Western Blot
Ctrl 2 F 55 - Histological stainings, Western Blot
Ctrl 3 F 60 - Histological stainings, Western Blot
Ctrl 4 F 73 - Western Blot
CAD: CADASIL patient; Ctrl: control patient. Applications were limited by sample amount and type (frozen or paraffin, see Material and methods).
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equipped with LAS LF software) microscope.
For immunohistochemical analysis of CAD 1–3 and
Ctrl 1–3 samples, 8-μm paraffin sections were deparaffi-
nized, rehydrated and antigens unmasked by boiling in
10 mM citrate buffer, pH 6.0 for 30 min. Blocking was
performed for 1 h in PBS/5% donkey serum and primary
antibodies incubated in PBS/1% donkey serum overnight
at 4°C. After three washes in PBS and blocking of en-
dogenous peroxidases with 0.3% hydrogen peroxide for
15 min, appropriate biotinylated secondary antibodies
(DAKO or Vector laboratories, 1:200) were applied for
1 h at room temperature. Development was performed
with avidin/biotin-horseradish peroxidase (HRP) com-
plex (Vectastain ABC-HRP kit, Vector Laboratories) and
3-amino-9-ethylcarbazole (AEC Peroxidase substrate Kit,
Vector Laboratories). To provide cytological detail, sec-
tions were counterstained with Mayer’s hematoxylin Solu-
tion (Sigma) for 1 min and rinsed in tap water for 10 min
prior to mounting with ProLong Gold. Sections were ex-
amined using the Axio Imager M2 microscope (Zeiss).
The following primary antibodies were used: goat poly-
clonal anti-collagen type IV (Southern Biotech, 1:500),
rabbit polyclonal anti-fibrillin-1 (kind gift of Lynn Sakai,
Shriners Research Center, Portland [36], 1:100), mouse
monoclonal anti-LTBP-1 (MAB388, R&D Systems, 1:50),
mouse monoclonal anti-fibronectin (F3648 Sigma, 1:300),
goat polyclonal anti-LAP (AF-246, R&D Systems, 1:50) or
rat monoclonal anti-Notch3-ECD (clone 2G8, raised against
the peptide NH2-RSFPGSPPGASNASC-COOH, kind gift
of Elisabeth Kremmer, Helmholtz Center, Munich, 1:10).
Sequential protein extraction
Protein extraction from purified brain vessels was per-
formed by modifying a previously published protocol
[30]. Vessels were homogenized in 50 mM Tris–HCl,
pH 7.5 using a TissueLyzer (Qiagen) with 5-mm beads
for 3 min at 50 Hz. After clearance by centrifugation
(5 min, 16,300 g), the Tris fraction was collected and thepellet resuspended in 50 mM Tris–HCl, pH 7.5, 1% SDS
for 30 min on ice. Centrifugation for 30 min at 16,300 g
yielded the SDS fraction and a pellet, which was resus-
pended in 50 mM Tris–HCl, pH 7.5, 1% SDS, 5% β-
mercaptoethanol (β-ME) for 30 min on ice while passing
through a 29-gauge needle 5 times. The β-ME fraction
was obtained by centrifugation for 30 min at 16,300 g.
Protease inhibitors (complete Mini EDTA-free, Roche)
were used throughout the extraction procedure.
Plasmids
The short human isoform of LTBP-1 (LTBP-1S) consisting
of 1395 amino acids (aa) was used throughout the study.
Constructs encoding full-length LTBP-1S and an N-
terminally truncated variant encoding aa 528–1395 with a
carboxy-terminal hemagglutinin (HA) tag (LTBP-1ΔN_
HA) [37] were kindly provided by Jorma Keski-Oja (Uni-
versity of Helsinki, Finland). Full-length LTBP-1S was
subcloned into the pEAK-12 vector (provided by Stefan
Lichtenthaler, DZNE, Munich) to harbour the CD5 signal
peptide, an N-terminal HA tag and a C-terminal V5-His
tag. LTBP-1ΔN containing a C-terminal V5-His tag (LTBP-
1ΔN_V5) was generated from the full-length clone and
LTBP-1ΔN_HA by restriction fragment cloning. A C-
terminally truncated LTBP-1 variant encoding aa 1–689
and a C-terminal V5-His tag (LTBP-1ΔC-V5) in the pTT5
vector [28] was constructed from full-length LTBP-1 by re-
striction fragment cloning. The N3EGF1-5 wild-type (WT)
and N3EGF1-5 C183R constructs used previously [28]
were modified to contain a C-terminal Halo tag (Promega).
Cell transfection
Human embryonic kidney (HEK) 293T cells were grown in
Dulbecco’s Modified Eagle‘s Medium (DMEM)-GlutaMAX
supplemented with 10% fetal calf serum and Penicillin/
Streptomycin (all from Gibco, Life Technologies). Small-
scale transfections were carried out in 24-well plates using
250 ng plasmid and Fugene (Roche) according to the
manufacturer’s protocol and serum-free conditioned
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fugation. The large-scale transfection procedure used for
protein purification from HEK293E cells has been de-
scribed earlier [28].
Protein purification
Purification of His-tagged proteins (LTBP-1ΔC_V5 and
LTBP-1ΔN_V5) was performed analogous to a protocol
previously described [28]. Purification of N3-EGF1-5
using the Halo System (Promega) will be described else-
where. Eluted fractions were analyzed by SDS-PAGE
followed by silver staining to verify the protein purity.
Protein concentrations were measured using the Qubit
protein assay (Life Technologies) or BCA Protein Assay
Kit (Pierce, Thermo Scientific) according to the manu-
facturer’s instructions.
SDS-PAGE, Western blot and silver staining
Proteins were separated on polyacrylamide gels (Minigel
system, BioRad) and either transferred onto Immobilon-
P Membrane (Millipore) using the semi-dry system
(Trans-Blot, BioRad) or processed for silver staining
(Roti-Black Kit, Roth). For Western blotting, membranes
were blocked with Tris-buffered saline (TBS)-0.05%
Tween/4% skim milk for 1 h and probed with the fol-
lowing primary antibodies in TBS-0.05% Tween/4% skim
milk overnight: mouse monoclonal anti-V5 (R960, Invi-
trogen, 1:1000), rat monoclonal anti-Notch3 ECD (clone
3G6, [28] 1:20), goat polyclonal anti-LAP (AF-246-NA,
R&D Systems, 1:500), mouse monoclonal anti-LTBP-1
(MAB388, R&D Systems, 1:500) and mouse monoclonal
anti-β-Tubulin (clone TUB 2.1, Sigma, 1:1000). Detection
was carried out using HRP-coupled secondary antibodies
(DAKO), chemiluminescence development (Immobilon
Western HRP Substrate, Millipore) and the Fusion FX7
imaging system (Vilber Lourmat).
Solid-phase binding assay
1 μg recombinant human Notch3 encompassing aa 40–
467 (N3EGF1-11-Fc) and IgG1-Fc (both R&D Systems)
were dissolved in PBS and coated onto Maxisorp 96-well
plates (Nunc) overnight at 4°C. After blocking with PBS/
1% BSA for 1 h, 50 μL conditioned supernatant from
HEK293T cells transfected with LTBP-1, LTBP-1ΔC_V5,
LTBP-1ΔN_HA or 100 ng purified LTBP-1ΔC_V5 in
PBS were allowed to bind for 1 h at room temperature.
Supernatant of mock-transfected cells or PBS was used
as a negative control. After washing, detection was per-
formed for 1 h using the following antibodies: mouse
monoclonal anti-V5 (R960, Invitrogen, 1:500) for LTBP-
1 and LTBP-1ΔC_V5; mouse monoclonal anti-LTBP-1
(MAB388, R&D Systems, 1:500) for LTBP-1ΔN_HA. Fol-
lowing incubation with anti-mouse-HRP (DAKO, 1:1000)
for 1 h, immune complexes were visualized by TMBMicrowell Peroxidase Substrate Kit (KPL) according to
the manufacturer’s protocol. For Western Blotting, bound
proteins were solubilized in Laemmli buffer.
Scanning for intensely fluorescent targets (SIFT)
The fluorescent labeling of proteins, incubation for pro-
tein aggregation and confocal single-particle analysis
were essentially performed as previously described [28].
Prior to the assay, labeled proteins were centrifuged at
100,000 g for 1 h at 4°C to remove preformed aggre-
gates. Protein concentrations used for aggregation exper-
iments were 64 nM (LTBP-1ΔC_V5 and LTBP-1ΔN_V5)
and 160 nM (N3EGF1-5 WT and N3EGF1-5 R183C).
SIFT measurements were performed after 24 h on an
Insight II Reader (Evotec-Technologies).
Statistical analysis
Data are expressed as mean and standard error of the
mean (SEM) of the indicated number of experiments.
Statistical analysis was performed using the Sigma Plot
12.5 software and the Mann–Whitney Test.
Results
Fibronectin and fibrillin-1 do not co-localize with
Notch3-ECD deposits
To study potential molecular mechanisms involved in me-
diating the toxicity of Notch3-ECD deposits post-mortem
brain material from five CADASIL patients and four
age- and sex-matched controls was analyzed by different
experimental approaches (Table 1). Immunohistochemical
staining of Notch3-ECD on paraffin-embedded sections
confirmed elevated immunoreactivity in the tunica media
of patient arterioles demonstrating the presence of Notch3-
ECD deposits (Figure 1). Next, fibronectin, fibrillin-1 and
latent transforming growth factor-β (TGF-β) binding pro-
tein 1 (LTBP-1), three ECM proteins with a known role in
TGF-β bioactivation [35], were analyzed. Fibronectin was
detected in moderate amounts in all layers of control
vessels, but showed a dramatic increase in the thick-
ened tunica adventitia and intima of CADASIL vessels
(Figure 1). Similarly, staining of fibrillin-1 was weak
in control vessels showing a fibrillar structure within
the tunica adventitia, but was markedly elevated in
CADASIL vessels resulting in the continuous labeling
of a thin layer at the perimeter of the tunica adventi-
tia (Figure 1). Thus, fibronectin as well as fibrillin-1
accumulate in CADASIL vessels, but their localization
appears to differ from Notch3-ECD. The lack of
spatial overlap was further demonstrated by immuno-
fluorescence co-staining of frozen patient brain sec-
tions for fibrillin-1 and Notch3-ECD (a similar
analysis for fibronectin was not possible due to the
lack of a suitable antibody). While Notch3-ECD was
exclusively detected as granular deposits typical for
Figure 1 Fibronectin and fibrillin-1 accumulate in CADASIL brain vessels. Paraffin-embedded brain sections of three CADASIL patients and
three healthy controls were stained for Notch3-ECD, fibronectin and fibrillin-1, counterstained with hematoxylin (blue) and analyzed by bright-field
microscopy. (CAD: CADASIL patient; Ctrl: control).
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showed a fibrous pattern not overlapping with Notch3-
ECD staining (Figure 2). These data suggested that
fibrillin-1 and fibronectin accumulation in CADASIL ves-
sels is not a result of recruitment into Notch3-ECD de-
posits, but rather a consequence of fibrotic processes. We,
therefore, excluded both proteins as direct participants in
Notch3-ECD aggregation.LTBP-1 is recruited to Notch3-ECD deposits
Members of the latent TGF-β binding protein (LTBP)
family, in particular LTBP-1, are key regulators of TGF-β
bioavailability within the ECM [38] and were found to
co-fractionate with Notch3-ECD deposits [30]. We
selected LTBP-1, the most prominent member of this
family, for analysis and performed immunofluorescence
staining on frozen brain sections. In control samples a
Figure 2 Fibrillin-1 and Notch3-ECD do not co-localize. Frozen brain sections from three CADASIL patients were co-stained for fibrillin-1 and
Notch3-ECD and analyzed by fluorescence microscopy. (CAD: CADASIL patient).
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was observed (Figure 3a). In contrast, staining was mark-
edly increased in CADASIL vessels and moreover re-
stricted to granules reminiscent of Notch3-ECD deposits,
as most clearly seen in capillaries. Indeed, co-staining
with Notch3-ECD yielded almost completely overlap-
ping signals in all patients examined (Figure 3b) sug-
gesting specific LTBP-1 recruitment into Notch3-ECD
deposits. To verify this finding by an alternative
method, we performed biochemical enrichment of
Notch3-ECD from isolated brain vessels using sequen-
tial protein extraction based on a protocol established
previously [30]. Immunoblotting of the final (β-ME-
containing) fraction for Notch3-ECD confirmed its
enrichment in CADASIL but not control vessels
(Figure 3c). Importantly, LTBP-1 showed a similar
fractionation behavior further suggesting an associ-
ation with Notch3-ECD (Figure 3c).
Latency-associated peptide (LAP) accumulates in the
tunica media of CADASIL vessels
The major biological function of LTBP-1 is the seques-
tration of latent TGF-β within the ECM by covalent
interaction with latency-associated peptide (LAP) [38,39].
We therefore analyzed LAP levels by immunoblotting of
the β-ME fraction of purified brain vessels (Figure 4a) as
well as by immunohistochemical staining of paraffin sec-
tions (Figure 4b) and detected a clear accumulation in pa-
tient, but not control samples. Most importantly, LAP
immunoreactivity was restricted to the tunica media
(Figure 4b), the vessel layer containing Notch3-ECD
deposits. Due to the lack of a suitable antibody, co-localization studies could not be performed. Nonetheless,
our findings suggest an LTBP-1-mediated sequestration of
LAP into Notch3-ECD aggregates and point to an involve-
ment of the TGF-β pathway in CADASIL pathogenesis.
LTBP-1 directly interacts with Notch3-ECD in vitro via its
N-terminus
Since recruitment of ECM proteins into Notch3-ECD
deposits might be facilitated by direct protein-protein
interactions [30], we investigated binding of LTBP-1 to
Notch3-ECD by applying a solid-phase binding assay, an
approach successfully used in the past to analyze inter-
action partners of Notch3 [29] or LTBP-1 [40]. Due to the
difficulty to purify correctly folded full-length Notch3-ECD
[28], a recombinantly generated Notch3-ECD fragment
comprising EGF-like repeats 1–11 and an IgG-Fc affinity tag
(N3EGF1-11-Fc) was used. Equally efficient immobilization
of N3EGF1-11-Fc and the control ligand IgG-Fc to microti-
ter plate wells was demonstrated by Western Blotting
(Additional file 1: Figure S1). LTBP-1 was provided in soluble
form by using conditioned supernatants of transfected
HEK293T cells. The amount of LTBP-1 bound to N3EGF1-
11-Fc was almost 5-fold increased in comparison to the
control ligand (Figure 5a). This was verified by SDS-PAGE
and immunoblotting of the material recovered from micro-
titer plates after assay completion revealing a prominent
high-molecular-weight band most likely representing
oligomeric LTBP-1 not dissolved under the solubilization
conditions used (Figure 5a). These findings suggested a
direct interaction between LTBP-1 and the first 11 EGF-
like repeats of the Notch3-ECD. To map the binding
domain within LTBP-1, two deletion constructs lacking
Figure 3 LTBP-1 accumulates in CADASIL brain vessels and co-localizes with Notch3-ECD aggregates. a Frozen brain sections from a
CADASIL patient and a healthy control containing an arteriole (left panels) or a capillary (right panels) were stained for LTBP-1 and analyzed by
fluorescence microscopy. b Frozen brain sections of three CADASIL patients were stained for LTBP-1 and Notch3-ECD and analyzed by confocal
fluorescence microscopy. c LTBP-1 co-fractionates with Notch3-ECD. The final (β-ME-containing) fractions of sequentially extracted brain vessels from
CADASIL patients and controls were immunoblotted for Notch3-ECD, LTBP-1 and β-tubulin. Shown is a representative blot from two independent
experiments. (CAD: CADASIL patient; Ctrl: control).
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main (LTBP-1ΔN) or the C-terminus containing the LAP
binding site (LTBP-1ΔC) were generated (Figure 5b). Ana-
lysis of conditioned supernatants from HEK293T cells
overexpressing either one of these constructs revealed sig-
nificant binding only for LTBP-1ΔC (Figure 5c). To ex-
clude an indirect interaction mediated by other factors
present in the supernatant, the binding assay was per-
formed with LTBP-1ΔC affinity-purified via its C-terminal
His tag (see Figure 6b) and revealed a binding capacity
similar to LTBP-1ΔC-containing supernatant (Figure 5c).
This finding suggested that the sequestration of LTBP-1
into Notch3-ECD deposits is mediated by a direct inter-
action involving its N-terminal region.
LTBP-1 co-aggregates with mutant Notch3
To provide proof for a direct participation of LTBP-1 in
the Notch3-ECD aggregation process, a previouslyestablished in vitro assay recapitulating the multimeriza-
tion of mutant Notch3 was used [27,28]. It is based on
scanning for intensely fluorescent targets (SIFT), a
unique technique allowing the quantitation of de novo
protein aggregation in solution [26]. Purified proteins
are labeled with different fluorescent dyes and pairwise
incubated to allow the formation of multimeric particles
whose size and relative composition is quantified by
SIFT and presented in a two-dimensional plot as
depicted in Figure 6a. While monomers and low-
molecular-weight oligomers are shown as low-intensity
signals, homomeric and heteromeric multimers are rep-
resented as mono-colored or dual-colored high-intensity
signals, respectively.
For our analyses we used the previously described wild-
type and R183C mutant-carrying Notch3 fragments
encompassing EGF-like repeats 1-5 (N3EGF1-5) [28] as
well as the LTBP-1 deletion variants LTBP-1ΔN and LTBP-
Figure 4 LAP accumulates in CADASIL brain vessels. a LAP co-fractionates with Notch3-ECD. The β-ME fractions of sequentially extracted
brain vessels from CADASIL patients and controls were immunoblotted for LAP and β-tubulin. Shown is a representative image of two independent
extractions. b LAP accumulates in the tuncia media of CADASIL patient vessels. Paraffin-embedded brain sections were stained for LAP and
counterstained with hematoxylin. (CAD: CADASIL patient; Ctrl: control).
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purification procedures used for fluorescent labeling (purity
of N3EGF1-5 wild-type was comparable to the R183C mu-
tant, data not shown). In line with our published data,
N3EGF1-5 R183C formed higher-order dual-color multi-
mers, while the corresponding wild-type fragment did not
show this tendency (Figure 6c). When LTBP-1ΔC or LTBP-
1ΔN were analyzed in combination with wild-type
N3EGF1-5, only single-color LTBP-1 multimers were
detected indicating self-aggregation, a finding already ob-
served in the solid-phase binding assay (see Figure 5a). Pre-
dominantly Notch3-containing multimers were obtained
when N3EGF1-5 R183C was combined with LTBP-1ΔN
lacking the Notch3 interaction domain (Figure 6c). In con-
trast, the combination of N3EGF1-5 R183C and LTBP-1ΔC
yielded dual-color multimers with a distribution typical for
mutant Notch3 fragments suggesting the generation of
aggregates containing both proteins. In summary, these
findings provide further support for our hypothesis that
LTBP-1 is a component of Notch3-ECD deposits.
Discussion
The accumulation and deposition of Notch3-ECD, an
early manifestation and hallmark of CADASIL [16], isconsidered the starting point of a chain of pathological
events eventually causing brain vessel dysfunction [9].
Motivated by recent evidence implicating the TGF-β
pathway in sporadic and familial SVD [32,33] and by the
identification of fibronectin, fibrillin-1 and members of
the LTBP family in brain fractions enriched for Notch3
deposits [30], we studied the role of these ECM constitu-
ents in CADASIL-related Notch3-ECD aggregation. For
fibronectin and fibrillin-1, fibril-forming glycoproteins
required for the LTBP-mediated sequestration of latent
TGF-β [35], we observe an enrichment in the tunica in-
tima and tunica adventitia of brain vessels from CADA-
SIL patients. A similar increase in fibronectin has
previously been reported in a single CADASIL case [41].
However, we do not detect co-localization with Notch3-
ECD deposits in the tunica media. This finding argues
against a direct involvement of fibronectin and fibrillin-1
in Notch3-ECD aggregation, but rather suggests that
their accumulation is due to a fibrotic process secondary
to Notch3-ECD deposition as previously reported for
various types of collagens [5,6].
In contrast, for LTBP-1, the most prominent member
of the LTBP family of TGF-β signaling regulators [38],
we find both an accumulation and a striking co-
Figure 5 LTBP-1 binds to immobilized Notch3 in a solid-phase
binding assay. a The interaction of full-length LTBP-1 derived from
conditioned cell supernatants with an immobilized Notch3 fragment
(N3EGF1-11-Fc) is increased 4.9-fold when compared to a control
ligand (IgG-Fc). Results are expressed as mean + SEM of seven
independent experiments. Bound LTBP-1 was re-evaluated by
immunoblotting and predominantly detected in oligomeric form.
b Schematic representation of the used LTBP-1 constructs and their
domain organization including cysteine-rich repeats (orange ovals), a
hybrid domain (grey ovals), EGF-like repeats (blue boxes) and V5-His or
HA tags (black circles). The fibronectin, TGF-β, and fibrillin-1 binding
regions are indicated. Note that LTBP-ΔC-HA was used in assays with
cell supernatants and LTBP-ΔC-V5 in assays requiring purified LTBP-1.
c LTBP-1 binding to Notch3 is mediated by its N-terminus. While the
N-terminal deletion variant LTBP-1ΔN does not bind significantly, the
C-terminal deletion variant LTBP-1ΔC, either from conditioned
supernatant or in purified form, shows significant interaction. Results
are expressed as mean + SEM of five (LTBP-1ΔC_V5) and four
(LTBP-1ΔN_HA) independent experiments. n.s.: not significant,
***p < 0.001; **p < 0.01; Mann–Whitney Test.
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http://www.actaneurocomms.org/content/2/1/96localization with Notch3-ECD deposits. The presence of
this finding in three unrelated patients carrying different
NOTCH3 mutations argued for its specificity and
prompted us to investigate the relationship between LTBP-
1 and Notch3-ECD in more detail. By applying a solid-
phase binding assay we detected a previously unknowndirect interaction between the LTBP-1 N-terminal domain
and the first 11 EGF-like repeats of Notch3-ECD. This
assay relied on the efficient immobilization of the Notch3
protein which could not be achieved with our Notch3-
ECD fragments encompassing EGF repeats 1–5 prevent-
ing a more precise mapping of the binding site. Likewise,
the effect of CADASIL mutations on the LTBP-1-Notch3
interaction could not be investigated since a mutant
EGF1-11 fragment was not available. Therefore, mutant-
specific effects were studied in a previously established
Notch3 aggregation assay [27,28]. While the LTBP-1 dele-
tion variant containing the Notch3 binding site showed
strong co-aggregation with the archetypal Notch3 mutant
R183C, this tendency was not observed with the variant
lacking the Notch3 interaction domain. Altogether, these
results strongly suggest the recruitment of LTBP-1 into
Notch3-ECD deposits by a co-aggregation mechanism re-
quiring a direct interaction.
Our observations extend previous results implicating
TIMP-3 and vitronectin in Notch3-ECD deposit forma-
tion [30]. In this study, also LTBP-2 and LTBP-4 had
been identified by mass spectrometry in human and
murine Notch3-ECD preparations, respectively, support-
ing our data on LTBP-1. The failure to detect it by the
proteomic approach might be due to the fact that, in-
stead of isolated vessels, whole brain tissue was used
possibly containing minute amounts of LTBP-1. Alterna-
tively, it might be generally difficult to detect LTBPs by
mass spectrometry, a possibility supported by the low
number of specific peptides assigned to LTBP-2 and
LTBP-4 [30]. LTBP-2 does not bind to TGF-β [42] and
was thus not investigated in our study. We attempted to
analyze LTBP-4 in our autopsy material and observed a
tendency towards enrichment in patient samples by im-
munoblotting of β-ME fractions. However, immunohis-
tological analyses could not be interpreted due to
unclear antibody specificity. Thus, further studies are re-
quired to assess the role of the individual LTBP family
members in the Notch3-ECD aggregation process.
TGF-β, a well-described regulator of blood vessel forma-
tion and homeostasis [43], is secreted from cells as inactive
complex consisting of the mature ligand, the TGF-β prodo-
main (also called latent TGF-β associated peptide, LAP) and
a member of the LTBP family. Sequestration within the
ECM is mediated by covalent interactions between LTBPs,
fibronectin and fibrillins resulting in the generation of a res-
ervoir of inactive TGF-β, from which the mature ligand can
be released by a variety of mechanisms including proteolysis
[35,38]. In agreement with this, we find increased levels of
LAP in the tunica media of CADASIL vessels indicating a
dysregulation of TGF-β signaling. Although co-localization
studies with Notch3-ECD could not be performed, our data
provide evidence for an involvement of the TGF-β pathway
in CADASIL pathogenesis.
Figure 6 LTBP-1ΔC specifically co-aggregates with mutant Notch3. a Notch3-ECD multimer formation is monitored by SIFT and data
illustrated in a 2D histogram: axes represent the intensity of photons per bin in the detector channel (green channel along the x-axis, red channel
along the y-axis). While monomers and homomeric multimers result in data points in the lower left histogram area and along the axes
respectively, heteromeric multimers are represented as high-intensity, dual-color signals in the white sector. b Purity of proteins used in the
aggregation assay. Shown are silver-stained gels containing the elution fractions after metal-ion matrix (LTBP-1ΔC or LTBP-1ΔN) or Halo-tag-mediated
purification (N3EGF1-5 R183C). c SIFT data from different protein combinations: while no high-molecular-weight particles are detected with N3EGF1-5
WT, typical aggregates are formed by N3EGF1-5 R183C and when combined with LTBP-1ΔC. In all other combinations homomeric multimers are
detected indicating self-aggregation. Shown are representative images of 2–5 experiments. WT: wild-type.
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in a variety of inherited diseases of the vasculature in-
cluding Marfan syndrome, an autosomal dominant sys-
temic connective tissue disorder primarily associated
with manifestations in the cardiovascular, skeletal and
ocular systems [44]. It is caused by mutations in
fibrillin-1 which lead to compromised microfibril func-
tion, reduced TGF-β sequestration and increased TGF-β
signaling activity. Elevated TGF-β levels have also been
reported in CARASIL, a rare recessively inherited form
of SVD sharing several features with CADASIL [45]. It is
caused by loss-of function mutations in the gene encod-
ing high temperature requirement protein A1 (HtrA1), a
conserved serine protease with a putative role in the
TGF-β pathway [33]. CARASIL mutations have been re-
ported to prevent processing of pathway components
and to result in elevated TGF-β signaling. Thus, it is
tempting to speculate that a dysregulation of TGF-β
activity might represent a common feature of bothCADASIL and CARASIL. More detailed analyses of the
different aspects of the TGF-β pathway in both diseases
are required to substantiate its role in inherited SVD.Additional file
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